Aktuellt
SENASTE
Redeye provides a research update on Alzinova following the company’s Q4 report published earlier today and recent clinical progress with lead candidate ALZ-101. We make some slight adjustments to our overall estimates following a revision of our model. However, we reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10 as we continue to have a positive outlook on the case.
LÄS MER
